- A half-page advert in each issue of the Newsletter
- A listing in the “Supporting Partners” section of the website with logo and direct link to company website
- The opportunity to advertise meetings and courses on the BACR website at no additional cost
- Advertise up to 5 jobs per year on the Job Shop page of the website free of charge.
- In addition two company individuals are eligible for complimentary membership of the Association.
- Please contact the BACR Secretariat if you would be interested in becoming a Supporting Partner.
Astex is a leader in innovative drug discovery and development, committed to the fight against cancer and diseases of the central nervous system.
Astex is developing a proprietary pipeline of novel therapies and has a number of partnered products being developed under collaborations with leading pharmaceutical companies. In October 2013, Astex was acquired by Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan, and operates, as a wholly owned subsidiary of Otsuka, from two sites with drug discovery research headquarters in Cambridge, UK and clinical development headquarters in Pleasanton, California, USA. The Otsuka Group employs approximately 42,000 people globally, and its products are available in more than 80 countries worldwide.
For more information about Astex Pharmaceuticals, please visit http://www.astx.com
For more information about Otsuka Pharmaceutical, please visit http://www.otsuka.com/en/
AstraZeneca has been generous in its support of BACR activities for many years. This includes the BACR/AstraZeneca Young Scientist Frank Rose Award, first given in 1993 to reward the achievement of a young scientist who had made a significant contribution to cancer research.
In recent years, the Award has been presented at the annual National Cancer Research Institute cancer conference. AstraZeneca continues to support this Award and selected BACR meetings of specific interest. The BACR wishes to express its gratitude to AstraZeneca for its continuing support.
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease in important areas of healthcare: gastrointestinal, cardiovascular, neuroscience, respiratory, cancer and infection. Backed by strong science and wide-ranging commercial skills, AstraZeneca is committed to the sustainable development of its business and the delivery of a flow of new medicines that bring benefit for patients and add value for wider society.
For more information about AstraZeneca, please visit http://www.astrazeneca.co.uk/home
Randox Biosciences is part of Randox Laboratories and is dedicated to advancing scientific discovery, drug development and diagnostics.
Randox Biosciences offers a comprehensive range of technologies and solutions to make oncology focused research become more efficient, cost effective and accurate.
Customers can select from a menu of over 85 off the shelf and novel oncology biomarkers creating a custom combination to be assayed on the award winning multiplex Biochip Array Technology.
Simply select relevant biomarkers from our extensive list and we’ll create your ideal multiplex array, choose from:
- Markers of inflammation
- Angiogenesis biomarkers
- Cell signalling markers
- Molecular markers of drug efficacy
Randox Biosciences also offers a rapid multiplex PCR array, which identifies 20 major mutations across the KRAS, BRAF and PIK3CA genes.
For more information on custom assay development or our KRAS multiplex array visit http://www.randoxbiosciences.com/kras-braf-pik3ca/ or e-mail email@example.com